levofloxacin has been researched along with suramin in 7 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (suramin) | Trials (suramin) | Recent Studies (post-2010) (suramin) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 3,023 | 92 | 431 |
| Protein | Taxonomy | levofloxacin (IC50) | suramin (IC50) |
|---|---|---|---|
| ATP-dependent 6-phosphofructokinase | Trypanosoma brucei brucei | 3 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 9.76 | |
| P2X purinoceptor 2 | Rattus norvegicus (Norway rat) | 4 | |
| DNA-dependent protein kinase catalytic subunit | Homo sapiens (human) | 1.7 | |
| DNA primase | Mycobacterium tuberculosis CDC1551 | 8.2 | |
| RmtA | Aspergillus nidulans | 5.9 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 9.4 | |
| NAD-dependent protein deacetylase sirtuin-2 | Homo sapiens (human) | 1.15 | |
| NAD-dependent protein deacetylase sirtuin-1 | Homo sapiens (human) | 1.5667 | |
| Protein arginine N-methyltransferase 1 | Homo sapiens (human) | 5.33 | |
| NAD-dependent protein deacylase sirtuin-5, mitochondrial | Homo sapiens (human) | 2.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Biswas, T; Garneau-Tsodikova, S; Green, KD; Tsodikov, OV | 1 |
7 other study(ies) available for levofloxacin and suramin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Discovery of inhibitors of Bacillus anthracis primase DnaG.
Topics: Animals; Bacillus anthracis; Cells, Cultured; DNA Primase; Doxorubicin; Drug Discovery; Enzyme Inhibitors; High-Throughput Screening Assays; Levofloxacin; Mice; Molecular Structure; Structure-Activity Relationship; Suramin; Tilorone | 2013 |